癌症患者的分子谱分析实现个体化联合治疗:I-PREDICT研究
I-PREDICT是一项跨机构前瞻性研究(NCT02534675),采用肿瘤DNA测序并及时推荐个体化联合治疗。49%的知情同意患者接受了个体化治疗,靶向更大比例分子改变(更高匹配评分)与显著改善的疾病控制率、无进展生存期和总生存期相关。
要点
- 定制多药联合方案可行,49%的知情同意患者接受了个体化治疗。
- 靶向更大比例的分子改变(更高匹配评分)与显著改善的疾病控制率相关。
- 更高匹配评分还与更长的无进展生存期和总生存期相关。
核心结论
- 个体化联合治疗在难治性恶性肿瘤患者中可行,靶向更大比例分子改变与显著改善的疾病控制率、无进展生存期和总生存期相关。
研究设计与样本
- 跨机构前瞻性研究(I-PREDICT,NCT02534675),使用肿瘤DNA测序并及时推荐个体化联合治疗。
主要发现
- 49%的知情同意患者接受了定制多药联合方案。
- 靶向更大比例已识别分子改变(更高匹配评分)与显著改善的疾病控制率、更长无进展生存期和总生存期相关,对比靶向较少体细胞改变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer treatments have evolved from indiscriminate cytotoxic agents to selective genome- and immune-targeted drugs that have transformed the outcomes of some malignancies1. Tumor complexity and heterogeneity suggest that the 'precision medicine' paradigm of cancer therapy requires treatment to be personalized to the individual patient2-6. To date, precision oncology trials have been based on molecular matching with predetermined monotherapies7-14. Several of these trials have been hindered by very low matching rates, often in the 5-10% range15, and low response rates. Low matching rates may be due to the use of limited gene panels, restrictive molecular matching algorithms, lack of drug availability, or the deterioration and death of end-stage patients before therapy can be implemented. We hypothesized that personalized treatment with combination therapies would improve outcomes in patients with refractory malignancies. As a first test of this concept, we implemented a cross-institutional prospective study (I-PREDICT, NCT02534675 ) that used tumor DNA sequencing and timely recommendations for individualized treatment with combination therapies. We found that administration of customized multidrug regimens was feasible, with 49% of consented patients receiving personalized treatment. Targeting of a larger fraction of identified molecular alterations, yielding a higher 'matching score', was correlated with significantly improved disease control rates, as well as longer progression-free and overall survival rates, compared to targeting of fewer somatic alterations. Our findings suggest that the current clinical trial paradigm for precision oncology, which pairs one driver mutation with one drug, may be optimized by treating molecularly complex and heterogeneous cancers with combinations of customized agents.
引用
- Sicklick JK, Kato S, Okamura R, et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med. 2019. PMID: 31011206. doi:10.1038/s41591-019-0407-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。